Chronic obstructive pulmonary disease (COPD) is a progressive lung disease which includes emphysema, chronic bronchitis, refractory asthma, and some forms of bronchiectasis. This disease is characterized by increasing breathlessness, wheezing, tightness in chest etc. In the early stages, there may be no symptoms but the symptoms gradually increases in later stages. Shortness of breath, chronic cough, fatigue, frequent flu, weight-loss etc. are the symptoms exhibited in the later stages. Spirometry, chest X-ray, arterial blood gas test etc. are the common tests for diagnosing COPD. Smoking, genetic factors and environmental pollution are some major risk factor that developed chronic obstructive pulmonary diseases.
Based on the Chronic Obstructive Pulmonary Disease (COPD) Drugs market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analyzed in detail. To Boost Growth during the epidemic era, this report analyzes in detail for the potential risks and opportunities which can be focused on.
In Chapter 2.4 of the report, we share our perspectives for the impact of COVID-19 from the long and short term.
In chapter 3.4, we provide the influence of the crisis on the industry chain, especially for marketing channels.
In chapters 8-13, we update the timely industry economic revitalization plan of the country-wise government.
Key players in the global Chronic Obstructive Pulmonary Disease (COPD) Drugs market covered in Chapter 5:
Cytokinetics
ZAI Lab
MediciNova
Boehringer Ingelheim
Almirall
AstraZeneca
Aquinox Pharmaceuticals
Chiesi Farmaceutici
Novartis
Mylan
Pharmaxis
Invion
Pearl Therapeutics
Ache Laboratorios Farmaceuticos
Asmacure
Astellas Pharma
Palobiofarma
Prosonix
Gilead Sciences
Mereo BioPharma
BioMarck Pharmaceuticals
Merck
Ario Pharma
Innoviva
F. Hoffmann-La Roche
Orion Corporation
In Chapter 6, on the basis of types, the Chronic Obstructive Pulmonary Disease (COPD) Drugs market from 2015 to 2025 is primarily split into:
Anticholinergic
Oral Corticosteroid
Beta2-agonists
Phosphodiesterase-4 (pde4) Inhibitors
Others
In Chapter 7, on the basis of applications, the Chronic Obstructive Pulmonary Disease (COPD) Drugs market from 2015 to 2025 covers:
Lung Functional Test
Chest x-ray Test
CT Scan
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 8-13:
North America (Covered in Chapter 9)
United States
Canada
Mexico
Europe (Covered in Chapter 10)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 11)
China
Japan
South Korea
Australia
India
South America (Covered in Chapter 12)
Brazil
Argentina
Columbia
Middle East and Africa (Covered in Chapter 13)
UAE
Egypt
South Africa
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025
Summary:
Get latest Market Research Reports on Chronic Obstructive Pulmonary Disease (COPD) Drugs. Industry analysis & Market Report on Chronic Obstructive Pulmonary Disease (COPD) Drugs is a syndicated market report, published as Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery. It is complete Research Study and Industry Analysis of Chronic Obstructive Pulmonary Disease (COPD) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.